Reinier was co-founder of early clinical CRO Xendo (now QPS) where he was responsible for the design of phase I/IIA clinical studies and for Marketing & Business Development. Currently serves as drug development consultant and as executive interim manager. Holds a PhD in Pharmacology from University of Amsterdam.

← Prof. Dr. Pieter de Graeff Mr. Edward van der Meer →